{"entity":{"id":"nct06538857","kind":"trial","name":"CEB-01 in Locally Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Standard surgery in pancreatic ductal adenocarcinoma, run by CEBIOTEX, now recruiting.","summary":"CEB-01 in Locally Resectable Pancreatic Cancer is a phase 2 interventional study registered as NCT06538857 by CEBIOTEX, with 39 participants planned, started 2024-08-20 and due to reach its primary completion in 2028-09. Interventions recorded: Standard surgery and CEB-01.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06538857","url":"https://clinicaltrials.gov/study/NCT06538857"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cebiotex"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06538857","phase":"2","setting":"Exploratory Clinical Trial to Assess Safety, Tolerability Efficacy and Pharmacokinetics of CEB-01 PLGA Membrane in Participants With Pancreatic Cancer.","sponsor":"CEBIOTEX","enrolled":39,"outcomes":[]},"route":"/trials/nct06538857/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/"}]}}